Psylo

We’re excited to share that Psylo, Tessara Therapeutics, and the Brain and Mind Centre, University of Sydney have been awarded a $3 million CRC-P grant to develop novel neuroplastogens for the treatment of substance use disorders! Together, we're accelerating the development of neuroplastogens, with a focus on methamphetamine addiction. This collaboration will leverage Psylo’s pioneering neuroplastogens, Tessara’s novel microtissue technology and the University of Sydney’s neuroscience expertise to address addiction and mental health challenges. We’re grateful for the support of the Australian Government and excited to join forces to develop innovative, brain-rewiring therapies that offer new hope for those struggling with addiction. 👉 Read more about this exciting project here: https://lnkd.in/gGjWkE_s 🧪 Joshua Ismin 💊 Sam Banister Nick Everett ⚗️ William Jorgensen Jin Tan Joanna Hare Lachlan Whish Mario de la Fuente, PharmD, PhD Dilara Bahceci Krista Licata Christos Papadimitriou Paul Adlard Alan Kozikowski Alex Kwan Graham Pechenik Dr. Jianmin Duan Anna Goldys Ryan Bethencourt Ian Torrance Eric J. Nestler, MD, PhD John Krystal Donald Gehlert, Ph.D. Forest Heims Main Sequence Tenmile Lionheart Ventures Focalpoint Partners Negev Capital Possible Ventures Startmate UNSW Founders Radar Ventures

The Psylo team had a fantastic day connecting with Scott Thompson and his team at the University of Colorado Anschutz Medical Campus to learn about the important research they’re leading on depression mechanisms and the action of antidepressants and psychedelics, right here in Colorado. We're thrilled to be part of this incredible ecosystem and look forward to contributing to the incredible research happening in our state! Devin Effinger, PhD, Joselyn Calderon, Jillian King, 💊 Sam Banister, Krista Licata, Dilara Bahceci, University of Colorado Boulder

In Psylo's latest Neuroscience Newsletter: New findings in anxiety, depression and addiction, brain connectivity, predicting efficacy, sex differences, neuroplasticity, new tools, and exploring molecular targets of psychedelics beyond 5-HT2A. 👉https://lnkd.in/g7SN7xw5

Check out how Psylo (Startmate, W21) and Enosis Therapeutics are using tech to tackle medicinal psychedelics 🦠 "Psylo has taken a different approach to psychedelic therapy by developing synthetic compounds inspired by psychedelics. Unlike psilocybin or MDMA, these compounds are designed to remove the hallucinogenic properties, offering patients the therapeutic benefits without the need for intense, supervised psychedelic experiences. 🧪 Joshua Ismin, co-founder and CEO of Psylo, explained the company is focused on creating novel compounds — known as neuroplastogens — which work on the same receptors as traditional psychedelics, but don’t induce hallucinations." Read more here!! https://lnkd.in/gz-DkJQE

I am delighted to be speaking at the 7th Neuropsychiatric Drug Development Summit in Boston next week! I will speak on the panel, "Navigating the Commercial Challenges of Reimbursement & Market Access to Streamline Route to Market for Psychiatric Therapeutics." I’ll be speaking alongside Dina Burkitbayeva (Freedom Biosciences), Charmaine Lykins (MapLight Therapeutics, Inc.) and Elemer Piros (Rodman & Renshaw), where we’ll address crucial questions such as: - How can we effectively commercialize neuropsychiatric products and secure payer support? - What strategies can help lower human resource costs to boost profitability? - How do we identify the most valuable areas for commercial investment in psychiatry? I'm looking forward to engaging with industry leaders and contributing to the future of psychiatric therapeutics. 🗓 September 26th at 4:00 PM 🤝 If you're attending, let’s connect! Registration link here: https://ter.li/0c7c90 World CNS Series Ellie Rapps The George Institute for Global Health Psylo

Psylo and Enosis: Advancing neuropsychiatric treatment with innovative technologies We're proud to be featured in SmartCompany alongside Enosis Therapeutics for our efforts to revolutionize neuropsychiatric treatment. While Enosis is harnessing virtual reality (VR) to enhance therapy, Psylo is at the forefront of drug discovery, developing novel neuroplastogens that provide the therapeutic benefits of psychedelics without inducing hallucinations. As Australia becomes a global test case for psychedelic-assisted therapies, we’re focused on making treatments more accessible, scalable, and effective. Our compounds target the same receptors as traditional psychedelics but with fewer side effects and faster action than current antidepressants. Read the full article, or reach out, to discover how we're shaping the future of neuropsychiatric treatments. https://lnkd.in/gz-DkJQE #Psylo #Biotech #MentalHealth #Neuropsychiatry 🧪 Joshua Ismin 💊 Sam Banister Dr Prash P. Agnieszka Sekula

We’re excited to announce that Dr. ⚗️ William Jorgensen, Psylo's Director of Medicinal Chemistry, will be a keynote speaker at the ASCEPT - Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists Drug Discovery SIG Student & ECR Symposium on September 11. Dr. Jorgensen is a highly accomplished EMCR and an emerging leader in the field, with extensive expertise in drug discovery, spanning academia, industry, and startups. He’s also a charismatic and engaging speaker — don’t miss this opportunity to hear him present! Register here: https://lnkd.in/gRp-ST8R #DrugDiscovery #MedicinalChemistry #ASCEPT #Pharmacology

🤝 Super cool to be able to meet up with the Biagon Inc. team in person to discuss founder-led biotech, psychedelics and 5-HT2A, and our work at Psylo. 🧑💻 David Cooper, David Minh, and Jim Tufts are building a cutting edge platform for predicting GPCR function and developing better drugs based on biophysical principles. 🥪 Lunch options limited by the sheer number of people in town for #ACSFall2024... Although the Snarf's logo looks like it was drawn during a Spravato treatment session, the sandwiches are excellent!

Psylo's CSO, Dr 💊 Sam Banister, is attending the American Chemical Society meeting in Denver this week. If you are also in town, please reach out - we'd love to connect and discuss the latest advancements in neurotherapeutics! #Psylo #Chemistry #Biotech #ACS2024

There are only 5 days left to cast your vote for #SXSW 2025 #PanelPicker. We'd love your vote for our proposals on #mentalhealth and #MCI / healthy #aging. The Future of Mental Health: Precision Neuromedicine: VOTE: https://lnkd.in/g2PXc4-r Featuring: Samantha Tabone, Partner, Focalpoint Partners 💊 Sam Banister, CSO & Co-founder, Psylo Jacob Robinson, CEO & Co-Founder, Motif Neurotech Ryan Field, CEO & CTO, Kernel Detecting and Delaying the Onset of Cognitive Decline: VOTE: https://lnkd.in/gBBjdMit Featuring Phyllis Ferrell, Chief Impact Officer, StartUp Health #AlzMoonshot Ken Mariash, CEO, Sinaptica Therapeutics Jen Flexman, PhD, MBA, COO & Co-founder, Moneta Health Ryan Field, CEO & CTO, Kernel